Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cyclenium, Haplogen team up in discovery collaboration
June 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

SHERBROOKE, Quebec & VIENNA, Austria—Pharmaceutical company Cyclenium Pharma Inc. has inked a research agreement with Haplogen GmbH to discover novel pharmaceutical candidates in multiple disease areas. The two companies will focus on certain antiviral Haplogen targets initially, and will phase-in additional targets in other therapeutic indications as research progresses. Haplogen brings with it unique haploid genetics technology and experience in host target identification, validation and screening, while Cyclenium can provide its CMRT Technology-derived QUEST Library and hit-to-lead optimization expertise.
 
“Cyclenium’s proprietary macrocyclic library appears ideal for use against the challenging antiviral and other targets identified using our haploid genetics platform,” said Dr. Georg Casari, CEO of Haplogen. “We look forward to working with their experienced and successful research team in progressing our drug discovery programs.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.